
Quality doesn’t always come cheap on the ASX. However, when strong ASX shares fall out of favour, opportunity can open up.
REA Group Ltd (ASX: REA), Pro Medicus Ltd (ASX: PME) and GQG Partners Inc. (ASX: GQG) are three high-profile names on the ASX that have seen their share prices retreat 20% or even 40% in the past 6 months. This despite retaining long-term growth drivers.
For investors willing to look past short-term volatility, these beaten-down ASX shares could offer attractive upside from current levels.
REA Group Ltd (ASX: REA)
REA Group shares have cooled significantly after a strong run over recent years. The ASX share pulled back sharply 21% in the past 6 months to $189.75 at the time of writing.
The fall of the blue chip share was a result of higher interest rates and softer housing activity that weighed on listing volumes and sentiment.
Despite that, REA’s underlying business remains one of the strongest digital marketplaces on the ASX. Realestate.com.au dominates Australian property listings, giving the company pricing power and resilient margins.
Revenue growth can slow when property markets cool, and regulatory scrutiny remains a risk, but history shows activity eventually rebounds. If housing turnover stabilises, REA’s earnings leverage could drive a renewed re-rating.
Most brokers see the ASX 200 share as a buy, with an average 12-month price target of $235.05. That points to a 45% upside.
Pro Medicus Ltd (ASX: PME)
This ASX healthcare share has also experienced a meaningful pullback after years of exceptional gains. The company’s share price surged as its medical imaging software won major hospital contracts globally, but valuation concerns and broader growth stock sell-offs have taken some heat out of the rally.
The ASX 200 share lost 42% of its value in the past 6 months and currently trades at $184.12 apiece. No wonder most analysts see serious upside ahead. The consensus price target for the ASX share is set at $296.19, a potential gain of 61% for the next 12 months.
Brokers think that Pro Medicus’ long-term story remains compelling. The ASX share operates a high-margin, capital-light business with sticky customers and recurring revenue.
The main risk lies in its premium valuation and reliance on hospital spending cycles, which can delay contract decisions. Even so, continued global rollout of its technology supports the case that recent weakness may represent an entry point rather than a warning sign.
GQG Partners Inc. (ASX: GQG)
GQG Partners rounds out the trio as a very different kind of opportunity. The price of the ASX share has drifted 23% lower over 6 months amid market volatility and periods of investor outflows.
As an active manager, GQG’s earnings are tied to assets under management, which can fall quickly when performance lags benchmarks. That said, the business still generates strong cash flows, operates with a low-cost structure and pays a generous dividend.
If markets improve and performance stabilises, sentiment could turn quickly. Market watchers rate the current valuation of $1.57 as overly pessimistic. They think the ASX share could climb to $2.06 in the next 12 months, a potential upside of 31%.
The post Why these beaten-down ASX shares are worth a second look appeared first on The Motley Fool Australia.
Should you invest $1,000 in REA Group right now?
Before you buy REA Group shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and REA Group wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 Jan 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why buy and hold investing with ASX shares could make you rich
- These were the worst-performing ASX 200 shares in January
- These 2 ASX shares are set to soar in 2026 and beyond
- Is AI a real threat to CAR Group and REA Group shares?
- The incredible ASX stock I’d hold for 10 years without watching the share price
Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Gqg Partners and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.








